Introducing Fitzpatrick's

BIOLOGICS HQ®

www.BiologicsHQ.com

BiologicsHQ is a new interactive web database that provides metrics and comprehensive analysis of aBLA activity, USPTO post grant proceedings and patent litigation for CDER-listed / 505(b)(2) biologic drugs.

BiologicsHQ Search
Free and predictive text search of the BiologicsHQ database

Search by biologic drug brand, scientific or company name

BiologicsHQ Statistics
Up-to-date metrics on biologics related USPTO post grant proceedings and patent litigations







BiologicsHQ Company Pages
provide information about biologic drug licensors

BiologicsHQ Product Pages
provide information for CDER-listed / 505(2)(b) biologic drugs

CELLTRION

FDA-Approved Biologics and Pending Applications

Inflectra®
Infliximab-dyyb
aBL 125544

Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada
Remsima (Celltrion) (January-2014)

Biosimilars Approved In The E.U.
Remsima (Celltrion) (September-2013)
Truxima (Celltrion) (February-2017)

Biosimilars Approved In Japan
Infliximab BS (Remsima) (Celltrion / Nippon Kayaku) (July-2014)

Biosimilars Approved In South Korea
Herzuma (CT-P6) (Celltrion) (January-2014)
Remsima (Celltrion) (July-2012)
Truxima (CT P10) (Celltrion) (November-2016)

Inter Partes Review Proceedings

Herceptin®
IPR2017-00959
IPR2017-01121
IPR2017-01122
IPR2017-01139
IPR2017-01140

Rituxan®
IPR2015-01733
IPR2015-01744
IPR2016-01614
IPR2016-01667
IPR2017-01093
IPR2017-01094
IPR2017-01095
IPR2017-01227
IPR2017-01229
IPR2017-01230

U.S. BPCIA / Biosimilar Litigation

Remicade®
1:14-cv-02256 (S.D.N.Y.)
1:14-cv-11613 (D. Mass.)
1:14-cv-07049 (S.D.N.Y.)
1:15-cv-10698 (D. Mass.)
1:16-cv-00071 (N.D. Utah)
1:16-cv-11117 (D. Mass.)

Related News Articles

The U.S. Biosimilars Market is Heating Up: Guidance from the Federal Circuit is Expected Late Spring

Robert S. Schwartz, Ph.D.; Corinne E. Atton
April 6, 2015

Click to view information concerning IPRs

Click to view information concerning patent litigations

Click to view "Spotlight On" report for this drug

Humira® (adalimumab)

BL 125057

U.S. License Holder:	Date of License:	Last Update:
AbbVie Inc.	**December-31-2002**	**April-28-2017**

FDA-Approved Indications

HUMIRA (adalimumab) is a tumor necrosis factor (TNF) blocker indicated for treatment of:

Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA;

Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older;

aBLA / 505(b)(2) Activity

aBLA / 505(b)(2) Approved by FDA
Amjevita: Amgen (September-2016)

aBLA / 505(b)(2) Accepted by FDA
BI 695501 Boehringer Ingelheim (January-2017)

Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.
Amgevita / Solymbic (Amgen) (March-2017)

Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):
IPR2017-00827 / IPR2017-01009
IPR2017-00826 / IPR2017-01008
IPR2017-00823

U.S. BPCIA / Biologics Litigation

PACER

Case No(s):
1:16-cv-00666 (D. Del.)
2:16-cv-00322 (E.D. Va.)

Related News Articles

Spotlight On Humira® (adalimumab)

Corinne E. Atton; April M. Breyer; Whitney L. Meier
April 10, 2017

For More Information On: www.BiologicsHQ.com

April M. Breyer
(212) 218-2561

Corinne E. Atton
(212) 218-2212

Fitzpatrick's Biotechnology/ Biologics Group:

Robert S. Schwartz, Ph.D.
(212) 218-2298

Brendan M. O'Malley, Ph.D.
(212) 218-2249

Business Development & Marketing:

Linda Ficano
(212) 218-2284